Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely aligns on key adverse effects and initiation dosing cues but omits critical label content (contraindications, use in specific populations) and cross-drug comparisons are unaddressed.
Category Scores
Accurate Statements
Vomiting is a reported side effect of Zepbound (tirzepatide), a GLP-1/GIP receptor agonist for weight loss.
6.1
Starting at low doses (2.5 mg) reduces risk.
2.1
Rates were higher than placebo (1-2%).
6.1
Most cases were mild to moderate.
6.1
Persistent cases may need dose adjustment.
2.1
Could signal dehydration.
5.3
Could signal gallbladder issues.
5.4
Could signal pancreatitis (rare, <1%).
5.5
Unsupported Statements
Clinical trials showed nausea in up to 25%.
Not verbatim in 6.1; exact percentage not clearly stated in labeling summary.
Clinical trials showed vomiting in 8-10% of patients.
Dose-specific percentages may not be presented in 6.1.
Vomiting often starting early and decreasing over time.
Time course not explicitly summarized in labeling.
In SURMOUNT trials, 5 mg dose: 8% experienced vomiting.
Dose-specific trial figures not guaranteed in 6.1.
In SURMOUNT trials, 10 mg dose: 9% experienced vomiting.
Dose-specific trial figures not guaranteed in 6.1.
In SURMOUNT trials, 15 mg dose: 10% experienced vomiting.
Dose-specific trial figures not guaranteed in 6.1.
Rates were dose-dependent.
Not explicitly stated in labeling summary; may be inferred from data elsewhere.
Taking it with food reduces risk.
Label does not mandate taking with meals to reduce GI risk.
Zepbound has similar vomiting rates to Wegovy.
Cross-drug comparison not provided in label.
Wegovy has vomiting rates of 5-11%.
Wegovy data not in this label.
Dual GLP-1/GIP action may slightly increase GI effects initially.
Label discusses mechanism but not explicit comparative rates.
Eat small, bland meals; avoid fatty/spicy foods.
Dietary counseling not in core labeling.
Hydrate; use ginger or OTC antiemetics.
OTC antiemetic guidance not in label.
Inject weekly on empty stomach if tolerated.
Label allows injection with or without regard to meals; 'empty stomach' is not specified.
Contradictions
Important Omissions
Contraindications (e.g., personal/family history of medullary thyroid carcinoma or MEN2), pregnancy and lactation guidance, pediatric safety data, and explicit use-in-populations details.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Adverse GI events are common but generally manageable; dehydration and gallbladder/pancreatic concerns are noted in label sections 5.3–5.5.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omissions of contraindication details and Use in Specific Populations; no explicit administration language clarification.
Suggested Improvement
Incorporate explicit contraindications (thyroid C-cell carcinoma risk, MEN2), pregnancy/pediatric guidance, and population-specific labeling; clarify administration guidance (no mandated 'empty stomach' requirement) and reference FDA-required sections (Contraindications and Use in Specific Populations).